← 返回前沿论文

新辅助治疗乳腺癌中的 TIL(肿瘤浸润淋巴细胞)评分

英文原题:Tumor-Infiltrating Lymphocyte Scoring in Neoadjuvant-Treated Breast Cancer.

查看英文原题

Tumor-Infiltrating Lymphocyte Scoring in Neoadjuvant-Treated Breast Cancer.

PubMed 2024/08/20(内容时间) Cancers (Basel) Q2 · IF 4.8(JCR 2025)

研究概要

新辅助化疗(NAC)现已成为局部晚期乳腺癌(BC)患者的标准治疗。

中文摘要

新辅助化疗(NAC)目前是局部晚期乳腺癌(BC)患者的标准治疗。TIL评分具有预后价值,并为NAC后残留肿瘤负荷评估增加预测价值。然而,NAC会引起肿瘤变化,NAC后样本中TIL评分的可靠性尚未得到研究。由两位经验丰富的病理学家对治疗前和治疗后BC组织的H&E染色和CD3/CD20双重显色IHC染色组织进行间质和瘤内TIL评分。使用HALO图像分析软件(版本2.2)进行数字TIL评分。在残留病灶患者中,我们显示H&E染色组织上间质TIL的病理学家间相关性良好(CCC值0.73)。两种染色方法评分(CCC 0.81)和数字TIL评分(CCC 0.77)也观察到良好相关性。然而,在完全缓解患者中,TIL评分的总体一致性较差。本研究表明,NAC治疗后存在可检测残留肿瘤的患者中,TIL评分具有良好的可靠性,与未治疗乳腺癌患者的评分相当。基于数字TIL评分观察到良好一致性,未来开发经过验证的算法可能具有优势。

展开英文摘要原文

Neoadjuvant chemotherapy (NAC) is now the standard of care for patients with locally advanced breast cancer (BC). TIL scoring is prognostic and adds predictive value to the residual cancer burden evaluation after NAC. However, NAC induces changes in the tumor, and the reliability of TIL scoring in post-NAC samples has not yet been studied. H&E- and dual CD3/CD20 chromogenic IHC-stained tissues were scored for stromal and intra-tumoral TIL by two experienced pathologists on pre- and post-treatment BC tissues. Digital TIL scoring was performed using the HALO image analysis software (version 2.2). In patients with residual disease, we show a good inter-pathologist correlation for stromal TIL on H&E-stained tissues (CCC value 0.73). A good correlation for scoring with both staining methods (CCC 0.81) and the digital TIL scoring (CCC 0.77) was also observed. Overall concordance for TIL scoring in patients with a complete response was however poor. This study reveals there is good reliability for TIL scoring in patients with detectable residual tumors after NAC treatment, which is comparable to the scoring of untreated breast cancer patients. Based on the good consistency observed with digital TIL scoring, the development of a validated algorithm in the future might be advantageous.

论文信息

作者
Thomas N、Garaud S、Langouo M、Sofronii D、Boisson A、De Wind A、Duwel V、Craciun L
单位
Molecular Immunology Unit, Institut Jules Bordet, 1070 Brussels, Belgium.Belgium
期刊
Cancers2024 Aug 20
原文标识
PubMed 39199667 · DOI 10.3390/cancers16162895